Aptevo Therapeutics Inc.
APVO
$4.30
-$0.48-10.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 120.58% | -738.89% | |||
| Gross Profit | -120.58% | 738.89% | |||
| SG&A Expenses | 13.79% | 18.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.54% | 22.42% | |||
| Operating Income | -1.54% | -22.42% | |||
| Income Before Tax | -1.52% | -23.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.52% | -23.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.52% | -23.74% | |||
| EBIT | -1.54% | -22.42% | |||
| EBITDA | -1.71% | -23.05% | |||
| EPS Basic | 43.18% | 56.78% | |||
| Normalized Basic EPS | 43.18% | 56.78% | |||
| EPS Diluted | 43.24% | 56.74% | |||
| Normalized Diluted EPS | 43.18% | 56.78% | |||
| Average Basic Shares Outstanding | 78.67% | 185.31% | |||
| Average Diluted Shares Outstanding | 78.67% | 185.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||